German-austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn - update 2008
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bundeszentrale für gesundheitliche Aufklärung, Köln: Aids von A bis Z; Neuauflage 2002.
Deutsche AIDS-Hilfe e.V: Der heutige Wissensstand 28. überarbeitete Auflage, 2002.
Mayaux MJ, Dussaix E, Isopet J, et al.: Maternal Virus Load during Pregnancy and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1: The French Perinatal Cohort Studies. J Infect Dis 1997, 175: 172–175. 10.1093/infdis/175.1.172
Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. N Engl J Med 1996, 335: 1621–1629. 10.1056/NEJM199611283352201
Cooper ER, Charurat M, Mofenson L, et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. JAIDS 2002, 29: 484–494.
Poirier MC, Divi RL, Al-Harthi L, et al.: Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. JAIDS 2003, 32: 175–183.
Barret B, Tardieu M, Rustin P, et al.: Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003, 17: 1769–1785. 10.1097/00002030-200308150-00006
Blanche S, Tardieu M, Rustin P, et al.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999, 354: 1084–1089. 10.1016/S0140-6736(99)07219-0
Poirier MC, Patterson TA, Slikker W Jr, Olivero OA: Incorporation of 3'-Azido-3'-Deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. JAIDS 1999, 22: 477–483. 10.1097/00126334-199912150-00008
Meng Q, Walker DM, Olivero OA, et al.: Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 2000, 97: 12667–12671. 10.1073/pnas.220203197
Scalfaro P, Chesaux JJ, Buchwalder PA, et al.: Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 1998, 24: 247–250. 10.1007/s001340050558
European Collaborative Study: Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. JAIDS 2003, 32: 380–387.
Wahn V: Routinemäßige Gabe von Zidovudin an HIV-infizierte Schwangere. Dt Ärztebl 1995, 92: A-3397–3398.
Frenkel LM, Cowles MK, Shapiro DE, et al.: Analysis of the Maternal Components of the AIDS Clinical Trial Group 076 Zidovudine Regimen in the Prevention of Mother-to-Infant Transmission of Human Immunodeficiency Virus Type 1. J Infect Dis 1997, 175: 971–974. 10.1086/514003
Landesmann SH, Kalish LA, Burns DN, et al.: Obstetrical Factors and The Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child. N Engl J Med 1996, 334: 1617–1623. 10.1056/NEJM199606203342501
Mandelbrot L, Le Chenadec J, Berrebi A, et al.: Perinatal HIV-1 Transmission. Interaction between Zidovudine Prophylaxis and Mode of Delivery in the French Perinatal Cohort. JAMA 1998, 280: 55–60. 10.1001/jama.280.1.55
Pitt J, Brambilla D, Reichelderfer P, et al.: Maternal Immunologic and Virologic Risk Factors for Infant Human Immunodeficiency Virus Type 1 Infection: Findings from the Women and Infants Transmission Study. J Infect Dis 1997, 175: 567–575. 10.1093/infdis/175.3.567
Rokos K, Wang H, Seeger J, et al.: Transport of Viruses Through Fetal Membranes: An In Vitro Model of Perinatal Transmission. J Med Virology 1998, 54: 313–319. 10.1002/(SICI)1096-9071(199804)54:4<313::AID-JMV12>3.0.CO;2-G
The European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996, 10: 1675–1681.
The European Collaborative Study: Immunological markers in HIV-infected pregnant women. AIDS 1997, 11: 1859–1865.
Tuomala RE, O'Driscoll PT, Bremer JW, et al.: Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. JID 2003, 187: 375–384. 10.1086/367706
Burns DN, Landesman S, Wright DJ, et al.: Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997, 175: 1206–1210. 10.1086/593569
Gaillard P, Verhofstede C, Mwanyumba F, et al.: Exposure to HIV-1 during delivery and mother-to-child transmission. AIDS 2000, 14: 2341–2348. 10.1097/00002030-200010200-00015
Wright TC Jr, Subbarao S, Ellerbrock TV, et al.: Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 2001, 184: 279–285. 10.1067/mob.2001.108999
Mwanyumba F, Gaillard P, Inion I, et al.: Placental inflammation and perinatal transmission of HIV-1. JAIDS 2002, 29: 262–269.
Kind Ch, Rudin Ch, Siegrist C, et al.: Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 1998, 12: 205–210. 10.1097/00002030-199802000-00011
Schäfer APA: Die HIV-Infektion in Geburtshilfe und Gynäkologie. Gynäkologe 1996, 29: 129–137.
Schäfer A, Friese K, Lauper U, et al.: Influence of cesarean section before parturition and antiretroviral prophylaxis on the materno-fetal transmission of HIV. 12th World AIDS Conference Geneva 1998. Poster LB 12466
Salzberger B, Marcus U, Vielhaber B, et al.: German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res 2004,9(11):491–504. [ http://www.daignet.deunterLeitlinien
Coll O, Fiore S, Floridia M, et al.: Pregnancy and HIV infection: A european consensus on management. AIDS 2002,16(Suppl 2):S1–18.
CDC Public Health Service Task Force: Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR 1998., 47/RR2:
CDC: Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. MMWR 1998., 47/RR-5:
Justman JE, Benning L, Danoff A, et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAIDS 2003, 32: 298–302. 10.1097/00126334-200303010-00009
Lorenzi P, Spicher VM, Laubereau B, et al.: (Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study): Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998,12(18):F241-F247. 10.1097/00002030-199818000-00002
Wimalasundera RC, Larbalestier N, Smith JH, et al.: Preeclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002, 360: 1152–1154. 10.1016/S0140-6736(02)11195-0
Tuomala RE, Shapiro DE, Mofenson LM, et al.: Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002, 346: 1863–1870. 10.1056/NEJMoa991159
Conley LJ, Ellerbrock TV, Bush TJ, et al.: HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002, 359: 108–113. 10.1016/S0140-6736(02)07368-3
Vandamme AM, Sonnerborg A, Ait-Khaled M, et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004,9(6):829–848.
Welles SL, Pitt J, Colgrove R, The Women and Infants Transmission Study Group: HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000, 14: 263–271. 10.1097/00002030-200002180-00008
Duwe S, Brunn M, Altmann D, et al.: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. JAIDS 2001, 26: 266–273. 10.1097/00126334-200103010-00010
Eastman PS, Shapiro DE, Coombs RW, et al.: Maternal Viral Genotypic Zidovudine Resistance and Infrequent Zidovudine Therapy to Prevent Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Pediatric Clinical Trial Protocol 076. J Infect Dis 1998, 177: 557–564. 10.1086/514228
Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al.: Lamivudine-Zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001, 285: 2083–2093. 10.1001/jama.285.16.2083
Jackson JB, Becker-Pergola G, Guay LA, et al.: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000, 14: F111-F115. 10.1097/00002030-200007280-00001
Eshleman SH, Hoover DR, Chen S, et al.: Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005,192(1):30–36. 10.1086/430764
Sustiva Capsules Product Monograph 1998
BMS Warning Letter, 5. January 2001
Rich KC, Siegel JN, Jennings C, et al.: CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis 1995, 172: 1221–1227. 10.1093/infdis/172.5.1221
Kosel BW, Beckerman KP, Hayashi S, et al.: Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003, 17: 1195–1199. 10.1097/00002030-200305230-00011
Mirochnick M, Fenton T, Gagnier P, et al.: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998, 178: 368–374.
Wang Y, Livingston E, Patil S, et al.: Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999, 180: 1536–1541. 10.1086/315067
Qian M, Bui T, Ho RJY, et al.: Metabolism of 3'-Azido-3'-Deoxythymidine (AZT) in Human Placental Trophopblasts and Hofbauer Cells. Biochemical Pharmacology 1994, 48: 383–389.
Agbaria R, Manor E, Barak J, et al.: Phosphorylation of 3'Azidothymidine in maternal and fetal peripheral blood mononuclear cells during gestation and and at term. JAIDS 2003, 32: 477–481. 10.1097/00126334-200304150-00002
Taylor GP, Lyall EGH, Back D, et al.: Pharmacological implications of lengthened in-utero exposure to nevirapine. Lancet 2000, 355: 2134–2135. 10.1016/S0140-6736(00)02383-7
Marzolini C, Rudin C, Decosterd LA, et al.: Transplacental passage of protease inhibitors at delivery. AIDS 2002, 16: 889–893. 10.1097/00002030-200204120-00008
Mirochnick M, Dorenbaum A, Holland D, et al.: Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002,21(9):835–838. 10.1097/00006454-200209000-00010
Mirochnick M, Dorenbaum A, Blanchard S, et al.: Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. JAIDS 2003,33(2):153–156. 10.1097/00126334-200306010-00006
Antiretroviral Pregnancy Registry Steering Committee: Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2007; Issued Dec 2007 available from url: www.apregistry.com
Larsen WJ: Human Embryology. New York: Churchill Livingstone; 1993.
Spielmann H, Steinhoff R, Schaefer C, et al.: Arzneiverordnung in Schwangerschaft und Stillzeit. 5. Aufl, Stuttgart, Gustav Fischer 1998.
Connor EM, Sperling RS, Gelber R, et al.: Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment. N Engl J Med 1994, 331: 1173–1180. 10.1056/NEJM199411033311801
Chuachoowong R, Shaffer N, Siriwasin W, et al.: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Inf Dis 2000, 181: 99–106. 10.1086/315179
Lallemant M, Jourdain G, Le Coeur S, et al.: A trial of shortened zidovudine regimens to prevent mother-to child transmission of human immunodeficiency virus type 1. N Eng J Med 2000, 343: 982–991. 10.1056/NEJM200010053431401
Wade NA, Birkhead GS, Warren BL, et al.: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998, 339: 1409–1414. 10.1056/NEJM199811123392001
Mbori-Ngacha D, Richardson BA, Overbaugh J, et al.: Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments. J Virol 2003, 77: 7702–7705. 10.1128/JVI.77.13.7702-7705.2003
Ekpini RA, Nkengasong JN, Sibailly T, et al.: Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002, 16: 625–630. 10.1097/00002030-200203080-00015
Sabbatini F, Prati F, Borghi V, et al.: Congenital pyelectasis in children born from mothers on Tenofovir containing therapy during pregnancy: report of two cases. Infection 2007, 35: 474–476. 10.1007/s15010-007-6358-7
Bardeguez AD, Shapiro DE, Mofenson LM, et al.: Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. JAIDS 2003, 32: 170–181. 10.1097/00126334-200302010-00009
Clarke JR, Braganza R, Mirza A, et al.: Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999, 59: 364–368. 10.1002/(SICI)1096-9071(199911)59:3<364::AID-JMV17>3.0.CO;2-V
O'Sullivan M, Boyer P, Scott G, et al.: The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol 1993, 168: 1510–1516.
Garcia PM, Kalish LA, Pitt J, et al.: Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Eng J Med 1999, 341: 394–402. 10.1056/NEJM199908053410602
Mofenson LM, Lambert JS, Stiehm ER, et al.: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Eng J Med 1999, 341: 385–393. 10.1056/NEJM199908053410601
The European Collaborative Study: Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999, 13: 1377–85.
Shaffer N, Roongpisuthipong A, Siriwasin W, et al.: Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J Inf Dis 1999, 179: 590–599. 10.1086/314641
Semprini AE: An international randomised trial of mode of delivery in HIV infected women. 12th World AIDS Conference Geneva 1998. Poster LB 23599
The International Perinatal HIV Group: The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Eng J Med 1999, 340: 977–987.
CDC: Recommendations of the U-S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus. MMWR 1994., 43/RR-11:
Grosch-Wörner I, Schäfer A, Obladen M, et al.: An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection. AIDS 2000, 14: 2903–2911. 10.1097/00002030-200012220-00012
Burns DN, Landesman S, Muenz LR, et al.: Cigarette smoking, premature rupture of membranes and vertical transmission of HIV1 among women with low CD4+ levels. JAIDS 1994, 7: 718–726.
Wensing MJ, Boucher CAB, van Kasteren M, et al.: Prevention of mother-tochild.transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS 2006, 20: 1465–1467. 10.1097/01.aids.0000233587.94961.4f
Stringer JSA, Sinkala M, Chapman V, et al.: Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003, 17: 1659–1665. 10.1097/00002030-200307250-00010
Taha TE, Kumwenda NI, Hoover DR, et al.: Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004,292(2):202–209. 10.1001/jama.292.2.202
Lallemant M, Jourdain G, Le Coeur S, et al.: Perinatal HIV Prevention Trial (Thailand) Investigators: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004,351(3):217–228. 10.1056/NEJMoa033500
Dabis F, Bequet L, Ekouevi DK, et al.: ANRS 1201/1202 DITRAME PLUS Study Group: Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005,19(3):309–318.
Garcia-Tejedor A, Perales A, Maiques V: Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet 2003,82(1):17–23. 10.1016/S0020-7292(03)00123-1
Deutsch-Österreichische Empfehlungen zur postexpositionellen Prophylaxe nach HIV-Exposition (September 2004) [ http://www.rki.de ]
Guay LA, Musoke P, Fleming T, et al.: Intrapartum and neonatal single dose nevirapine compares with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda. HIVNET 012 randomized trial. Lancet 1999, 354: 795–802.
Moodley D, Moodley J, Coovadia H, et al.: A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003, 187: 725–735. 10.1086/367898
Flys T, Nissley DV, Claasen CW, et al.: Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005,192(1):24–29. 10.1086/430742
Marcus U: AIDS und HIV-Infektionen bei Frauen und Kindern in Deutschland. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 1999, 42: 553–557. 10.1007/s001030050154
Shapiro D, Tuomala R, Samelson R, et al.: Abstract 12953, 9th Conference on Retroviruses and Opportunistic Infections, Seattle. 2002.
Ioannidis JPA, Abrams EJ, Ammann A, et al.: CM: Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J Inf Dis 2001, 183: 539–545. 10.1086/318530
Mandelbrot L, Burgard M, Teglas J-P, et al.: Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999, 13: 2143–2149. 10.1097/00002030-199910220-00018
Debiaggi M, Zara F, Spinillo A, et al.: Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Microbiol Infect Dis 2001, 20: 91–96.
Ellerbrock TV, Lennox JL, Clancy KA, et al.: Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001, 184: 28–36. 10.1086/321000
Si-Mohamed A, Kazatchkine MD, Goujon C, et al.: Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000, 182: 112–122. 10.1086/315679
Avidan MS, Groves P, Blott M, et al.: Low complication rate associated with cesarean section under spinal anesthesia for HIV-1-infected women on antiretroviral therapy. Anesthesiology 2002,97(2):320–324. 10.1097/00000542-200208000-00006
Read J, Tuomala R, Kpamegan E, et al.: Mode of delivery and postpartum morbidity among HIV-infected women: the women and infants transmission study. JAIDS 2001, 26: 236–245. 10.1097/00126334-200103010-00005
Rodriguez EJ, Spann C, Jamieson D, et al.: Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. Am J Obstet Gynecol 2001, 184: 1108–1111. 10.1067/mob.2001.115179
Watts DH, Lambert JS, Stiehm ER, et al.: Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. Am J Obstet Gynecol 2000, 183: 100–107.
European Collaborative Study and the Swiss Mother + Child HIV Cohort Study: Combination antiretroviral therapy and duration of pregnancy. AIDS 2000, 14: 2913–2920.
Nduati R, John G, Mbori-Ngacha D, et al.: Effect of breastfeeding and formula feeding on Transmission of HIV-1. JAMA 2000, 283: 1167–1174. 10.1001/jama.283.9.1167
Van de Perre P: Transmission of human immunodeficiency virus type 1 through breast-feeding: how can it be prevented? J Infect Dis 1999,179(Suppl 3):S405–407.
Nduati RW, John GC, Richardson BA, et al.: Human immunodeficiency virus type 1 infected cells in breast milk. Infect Dis 1995, 172: 1461–1468. 10.1093/infdis/172.6.1461
Thiry L, Spencer-Goldberger S, Jonckheer Tetal: Isolation of AIDS virus from cell-free breastmilk of three healthy virus carriers. Lancet 1985, ii: 891–892.
Haas J, Geiss M, Böhler T, et al.: False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus type 1 in children infected with HIV strains of African origin. J Infect Dis 1996, 174: 224–225.
Rossi P, et al.: Early diagnosis of HIV infection in infants - Report of a consensus workshop, Siena, Italy, January 17–18, 1992. JAIDS 1992, 5: 1168–1178.
CENTERS OF DISEASE CONTROL: Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998, 47: 1–43. [ http://www.hivatis.org ]
Capparelli EV, Mirochnick M, Dankner WM, et al.: Pediatric AIDS Clinical Trials Group 331 Investigators: Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003,142(1):47–52. 10.1067/mpd.2003.mpd0335
Maiques V, Garcia-Tejedor A, Perales A, et al.: HIV detection in amniotic fluid samples. Amniocentesis can be performed in HIV pregnant women? Eur J Obstet Gynecol Reprod Biol 2003,108(2):137–141. 10.1016/S0301-2115(02)00405-0
Davies G, Wilson RD, Desilets V, et al.: Society of Obstetricians and Gynaecologists of Canada: Amniocentesis and women with hepatitis B, hepatitis C or human immunodeficiency virus. J Obstet Gynaecol Can 2003,25(2):145–148. 149–152
Poirier MC, Olivero OA, Walker DM, et al.: Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004,199(2):151–161. 10.1016/j.taap.2003.11.034
Mirochnick M, Capparelli E, et al.: Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004,43(15):1071–1087. 10.2165/00003088-200443150-00002
Lyons FE, Coughlan S, Byrne CM, et al.: Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005,19(1):63–67. 10.1097/00002030-200501030-00007
Nolan M, Fowler MG, Mofenson LM: Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr 2002,30(2):216–29.
Thorne C, Patel D, Newell ML: Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004,18(17):2337–2339.
Fiore S, Newell ML, Thorne C: European HIV in Obstetrics Group: Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 2004,18(6):933–938.
Marcollet A, Goffinet F, Firtion G et al: Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002,186(4):784–789. 10.1067/mob.2002.122251
Kovacs A, Wasserman SS, Burns D, et al.: DATRI Study Group; WIHS Study Group: Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001,358(9293):1593–1601. 10.1016/S0140-6736(01)06653-3
Fiore JR, Suligoi B, Saracino A, et al.: Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003,17(15):2169–2176. 10.1097/00002030-200310170-00004
Brennan-Benson p, Pakianathan M, Rice P, et al.: Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross plcenta. AIDS 2006, 20: 297–299. 10.1097/01.aids.0000200535.02232.1b
Chaix ML, Dabis F, Ekouevi D, et al.: Addition of 3 Days of ZDV+3TC Postpartum to a Short Course of ZDV+3TC and Single-dose NVP Provides Low Rate of NVP Resistance Mutations and High Efficacy in Preventing Peri-partum HIV-1 Transmission: ANRS DITRAME Plus, Abidjan, Côte d'Ivoire. 12th CROI, Boston 2005. Abstr. 72LB
Ripamonti D, Cattaneo D, Maggiolo F, et al.: Atazanavir plus low.dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007, 21: 2409–2415. 10.1097/QAD.0b013e32825a69d1
Ioannidis JP, Contopoulos-Ioannidis DG: Maternal viral load and the risk of perinatal transmission of HIV-1. N Engl J Med 1999,341(22):1698–1700.
Chappuy H, Treluyer JM, Rey E, et al.: Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004,191(2):558–562. 10.1016/j.ajog.2004.01.034
Feiterna-Sperling C, Piening T, Casteleyn S: Use of lopinavir (LPV/r) during pregnancy. Eur J Med Res 10(Supplement II): S. 89 P161
Meyohas MC, Lacombe K, Carbonne B, et al.: Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS 2004,18(14):1966–1968. 10.1097/00002030-200409240-00017
Morris A, Juethner S, Theroux E: Atazanavir use in pregnancy. Third International AIDS Society Conference on HIV Pathogenesis and Therapy, Rio, poster presentation TuPe5.2p01. 2005.
Dunn DT, Brandt CD, Kirvine A, et al.: The sensitivity of HIV1-DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995,9(9):F7–11.
Chaisilwattana P, Chokephaibulkit K, Chalermchockcharoenkit A, et al.: Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 2002,35(11):1405–1413. 10.1086/344274
European collaborative study: HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001,15(6):761–770.
European Collaborative Study: Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005,40(3):458–465.
Ananworanich J, Siangphoe U, Hill A, et al.: Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. JAIDS 2005,39(5):523–529.
Pellegrin I, Thiebaut R, Blanco P, et al.: Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4(+) cells/microl? Impact on immunovirological parameters. J Med Virol 2005,77(2):164–172. 10.1002/jmv.20452
Tarantal AF, Marthas ML, Shaw JP, et al.: Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20: 323–333. 10.1097/00042560-199904010-00001
Hughes S, Hughes A, Brothers C, The CNA106030 Study Team, et al.: PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat 2007, in press.
Warszawski J, Tubiana R, Le Chenadec J, et al.: Mother to child HIV transmission despite antiretroviral therapy in the ARNS French Perinatal Cohort. AIDS 2008, 22: 289–299. 10.1097/QAD.0b013e3282f3d63c
Mofenson LM: Efavirenz reclassified as FDA pregnancy category D. AIDS Clin Care 2005,17(2):17.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006,355(22):2283–96.
Gingelmaier A, Hollwitz B, Casteleyn S, et al.: Schwangerschaftsverlauf und kindliches Outcome bei 599 HIVexponierten Schwangerschaften an deutschen Schwerpunktzentren 1999–2003. Geburtshilfe und Frauenheilkunde 2005, 65: 1058–1063. 10.1055/s-2005-872993